- Home
- AUPH
as 04-23-2025 4:00pm EST
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Founded: | 1993 | Country: | Canada |
| Employees: | N/A | City: | EDMONTON |
| Market Cap: | 999.8M | IPO Year: | 1999 |
| Target Price: | $11.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.77 - $10.67 | Next Earning Date: | 05-05-2025 |
| Revenue: | $235,133,000 | Revenue Growth: | 33.97% |
| Revenue Growth (this year): | 11.86% | Revenue Growth (next year): | 24.96% |
Stock Insider Trading Activity of Aurinia Pharmaceuticals Inc (AUPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Keenan Greg | AUPH | Chief Medical Officer | Mar 7 '25 | Sell | $8.23 | 8,305 | $68,350.15 | 153,484 | |
| TANG KEVIN | AUPH | Director | Feb 28 '25 | Buy | $7.98 | 1,600,000 | $12,713,125.64 | 8,929,500 | |
| Greenleaf Peter | AUPH | Chief Executive Officer | Feb 28 '25 | Sell | $7.96 | 360,540 | $2,871,124.24 | 1,953,892 | |
| Miller Joseph M | AUPH | Chief Financial Officer | Feb 28 '25 | Sell | $7.96 | 118,013 | $939,611.68 | 577,361 | |
| Donley Matthew Maxwell | AUPH | Chief Operating Officer | Feb 28 '25 | Sell | $7.96 | 124,893 | $994,424.72 | 739,456 | |
| Robertson Stephen P. | AUPH | EVP, General Counsel | Feb 28 '25 | Sell | $7.96 | 122,479 | $975,223.44 | 509,276 | |
| Keenan Greg | AUPH | Chief Medical Officer | Feb 28 '25 | Sell | $8.00 | 12,239 | $97,912.00 | 153,484 |
Latest Aurinia Pharmaceuticals Inc News
AUPH Breaking Stock News: Dive into AUPH Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
High Growth Tech Stocks To Watch In The US Market
Simply Wall St.
22 days ago
Declining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?
Insider Monkey
a month ago
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March
Zacks
a month ago
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
Barrons.com
2 months ago
Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors
Simply Wall St.
2 months ago
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point
Zacks
2 months ago
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?
Simply Wall St.
2 months ago
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Compare AUPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUPH Aurinia Pharmaceuticals Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.